3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
88
Neoplasm Metastasis
4
HER2-positive Breast Cancer
4
Stomach Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Thyroid Neoplasms
1
Thrombocytosis
1
Sarcoma
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Patient Preference
1
Pathologic Complete Response
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Metastatic HER2-positive Breast Cancer With Brain Metastasis
1
Interventions
Surveys and Questionnaires
7
Nivolumab
5
atezolizumab
3
Radiosurgery
3
Blood Specimen Collection
3
pertuzumab
2
pembrolizumab
2
pazopanib
2
cemiplimab
2
amminedichloro(2-methylpyridine)platinum(II)
2
alectinib
2
Magnetic Resonance Spectroscopy
2
Interviews as Topic
2
Drug Therapy
2
Capecitabine
2
tepotinib
1
talazoparib
1
selpercatinib
1
pralsetinib
1
ponatinib
1
pemigatinib
1
palbociclib
1
motexafin gadolinium
1
montanide ISA 51
1
mannide monooleate
1
itacitinib
1
ipatasertib
1
fludarabine
1
entrectinib
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
Ado-Trastuzumab Emtansine
×
Breast
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled